Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jun 25, 2019 in Leukemia | 0 comments

In a nutshell

This study looked at the use of blood markers to measure treatment activity of L-asparaginase in acute lymphoblastic leukemia (ALL). Researchers found that antithrombin (AT) and fibrinogen (FIB) could be used to measure effective levels of L-asparaginase in these patients. 

Some background

L-asparaginase is a treatment for acute lymphoblastic leukemia (ALL). It is obtained from a bacteria called E. coli. This may lead to allergic reactions which may reduce effectiveness. Antithrombin (AT) and fibrinogen (FIB) are blood markers involved in clotting. It is not known if these markers may be used to measure treatment activity of L-asparaginase

Methods & findings

97 patients with ALL treated with L-asparaginase were included in this study. Blood markers such as AT, FIB, and other proteins were measured. L-asparaginase activity was also measured.

A higher activity of AT, FIB and protein levels was linked with lower effective levels of L-asparaginase in these patients.

The bottom line

The study concluded that AT combined with FIB may be good markers of L-asparaginase activity in patients with ALL.

The fine print

This study had a small sample size. Larger studies may be needed to confirm results.

Published By :

Pediatric blood & cancer

Date :

Apr 02, 2019

Original Title :

Antithrombin and fibrinogen levels as predictors for plasma L-asparaginase activity in children with acute lymphoblastic leukemia.

click here to get personalized updates